Gold prices steady ahead of Fed decision; weekly weakness noted
AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN), a leading global biopharmaceutical company, disclosed in a recent SEC filing that Non-Executive Director Karen Knudsen has purchased 1,400 American Depositary Shares (ADSs) of the company. The transaction took place on April 30, 2025, with the ADSs priced at $71.655 each, amounting to a total investment of over $100,000.
This purchase aligns with the company’s report for the month of May 2025, as filed with the Securities and Exchange Commission. The ADSs, traded under the ticker symbol AZN on the Nasdaq, represent a stake in AstraZeneca (NASDAQ:AZN)’s equity. Each ADS corresponds to one-half of an AstraZeneca ordinary share.
The transaction was conducted on the Nasdaq Global Select Market (XNAS) and is detailed in the notification attached to the SEC filing. The disclosure is made in accordance with the EU Market Abuse Regulation, which is part of UK law following the European Union (Withdrawal) Act 2018.
AstraZeneca focuses on the discovery, development, and commercialization of prescription medicines, particularly in the areas of Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Headquartered in Cambridge, UK, the company’s products are available in over 125 countries and serve millions of patients globally.
The information provided in this article is based on AstraZeneca’s Form 6-K filing with the SEC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.